Liver Cirrhosis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Recent Developments | Astrazeneca, Bayer, Sanofi, Pfizer, Merck, Novartis

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Liver Cirrhosis pipeline constitutes 50+ key companies continuously working towards developing 50+ Liver Cirrhosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Liver Cirrhosis Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Liver Cirrhosis Market.

The Liver Cirrhosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Liver Cirrhosis Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Liver Cirrhosis treatment therapies with a considerable amount of success over the years.

*
Liver Cirrhosis companies working in the treatment market are PharmaIN, Gwo Xi Stem Cell Applied Technology Co., Ltd., Lipocine Inc., Calliditas Therapeutics, Galectin Therapeutics, Zydus Therapeutics, CymaBay Therapeutics, and others, are developing therapies for the Liver Cirrhosis treatment

*
Emerging Liver Cirrhosis therapies in the different phases of clinical trials are- PHIN-214, GXHPC1, LPCN 1148, Setanaxib, Belapectin, Saroglitazar, Seladelpar, and others are expected to have a significant impact on the Liver Cirrhosis market in the coming years.

*
In October 2024, Supernus Pharmaceuticals announced that its candidate SPN-820 showed a "rapid and significant" impact in a Phase IIa trial for adults with major depressive disorder (MDD). The study (NCT06235905) achieved its primary endpoint, demonstrating a clinically significant improvement of -6.1 on the Hamilton Depression Rating Scale-6 items (HAM-D6) at two hours, which increased to -9.6 by day 10. Additionally, suicidal ideation decreased by 80%, dropping from 12.5% at baseline to 2.6% by day ten.

*
In January 2023, CymaBay Therapeutics declared that it has partnered with Kaken Pharmaceutical to develop and market eladelpar, one of CymaBay's experimental medications, in Japan for the treatment of primary biliary cholangitis.

Liver Cirrhosis Overview

Liver cirrhosis is a late stage of scarring (fibrosis) of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcoholism. The liver carries out several necessary functions, including detoxifying harmful substances in your body, cleaning your blood, and making vital nutrients. Cirrhosis can lead to a number of complications, including liver cancer.

Get a Free Sample PDF Report to know more about Liver Cirrhosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/liver-cirrhosis-pipeline-insight [https://www.delveinsight.com/report-store/liver-cirrhosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Liver Cirrhosis Drugs Under Different Phases of Clinical Development Include:

*
PHIN-214: PharmaIN

*
GXHPC1: Gwo Xi Stem Cell Applied Technology Co., Ltd.

*
LPCN 1148: Lipocine Inc.

*
Setanaxib: Calliditas Therapeutics

*
Belapectin: Galectin Therapeutics

*
Saroglitazar: Zydus Therapeutics

*
Seladelpar: CymaBay Therapeutics

Liver Cirrhosis Route of Administration

Liver Cirrhosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Inhalation

*
Inhalation/Intravenous/Oral

*
Intranasal

*
Intravenous

*
Intravenous/ Subcutaneous

*
NA

*
Oral

*
Oral/intranasal/subcutaneous

*
Parenteral

*
Subcutaneous

Liver Cirrhosis Molecule Type

Liver Cirrhosis Products have been categorized under various Molecule types, such as

*
Antibody

*
Antisense oligonucleotides

*
Immunotherapy

*
Monoclonal antibody

*
Peptides

*
Protein

*
Recombinant protein

*
Small molecule

*
Stem Cell

*
Vaccine

Liver Cirrhosis Pipeline Therapeutics Assessment

*
Liver Cirrhosis Assessment by Product Type

*
Liver Cirrhosis By Stage and Product Type

*
Liver Cirrhosis Assessment by Route of Administration

*
Liver Cirrhosis By Stage and Route of Administration

*
Liver Cirrhosis Assessment by Molecule Type

*
Liver Cirrhosis by Stage and Molecule Type

DelveInsight's Liver Cirrhosis Report covers around 50+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Liver Cirrhosis product details are provided in the report. Download the Liver Cirrhosis pipeline report to learn more about the emerging Liver Cirrhosis therapies [https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Liver Cirrhosis Therapeutics Market include:

Key companies developing therapies for Liver Cirrhosis are - Astrazeneca, Bayer, Sanofi, Pfizer, Merck & Co., Novartis, Hoffmann-La Roche, Takeda, Gilead Sciences, Shionogi Inc., Promethera, and others.

Liver Cirrhosis Pipeline Analysis:

The Liver Cirrhosis pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Liver Cirrhosis with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Liver Cirrhosis Treatment.

*
Liver Cirrhosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Liver Cirrhosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Liver Cirrhosis market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Liver Cirrhosis drugs and therapies [https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Liver Cirrhosis Pipeline Market Drivers

*
Increasing Prevalence for the treatment of Liver Cirrhosis, increase in the growing government initiatives and rising awareness are some of the important factors that are fueling the Liver Cirrhosis Market.

Liver Cirrhosis Pipeline Market Barriers

*
However, side-effects associated with the treatment of Liver Cirrhosis, high cost associated with the treatment and other factors are creating obstacles in the Liver Cirrhosis Market growth.

Scope of Liver Cirrhosis Pipeline Drug Insight

*
Coverage: Global

*
Key Liver Cirrhosis Companies: PharmaIN, Gwo Xi Stem Cell Applied Technology Co., Ltd., Lipocine Inc., Calliditas Therapeutics, Galectin Therapeutics, Zydus Therapeutics, CymaBay Therapeutics, and others

*
Key Liver Cirrhosis Therapies: PHIN-214, GXHPC1, LPCN 1148, Setanaxib, Belapectin, Saroglitazar, Seladelpar, and others

*
Liver Cirrhosis Therapeutic Assessment: Liver Cirrhosis current marketed and Liver Cirrhosis emerging therapies

*
Liver Cirrhosis Market Dynamics: Liver Cirrhosis market drivers and Liver Cirrhosis market barriers

Request for Sample PDF Report for Liver Cirrhosis Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Liver Cirrhosis Report Introduction

2. Liver Cirrhosis Executive Summary

3. Liver Cirrhosis Overview

4. Liver Cirrhosis- Analytical Perspective In-depth Commercial Assessment

5. Liver Cirrhosis Pipeline Therapeutics

6. Liver Cirrhosis Late Stage Products (Phase II/III)

7. Liver Cirrhosis Mid Stage Products (Phase II)

8. Liver Cirrhosis Early Stage Products (Phase I)

9. Liver Cirrhosis Preclinical Stage Products

10. Liver Cirrhosis Therapeutics Assessment

11. Liver Cirrhosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Liver Cirrhosis Key Companies

14. Liver Cirrhosis Key Products

15. Liver Cirrhosis Unmet Needs

16 . Liver Cirrhosis Market Drivers and Barriers

17. Liver Cirrhosis Future Perspectives and Conclusion

18. Liver Cirrhosis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=liver-cirrhosis-pipeline-trends-2024-clinical-trials-therapeutic-innovations-and-recent-developments-astrazeneca-bayer-sanofi-pfizer-merck-novartis]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.